88 related articles for article (PubMed ID: 21856552)
21. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
[TBL] [Abstract][Full Text] [Related]
22. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother (1991); 2001 May; 24(3):272-279. PubMed ID: 11395644
[TBL] [Abstract][Full Text] [Related]
23. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
[TBL] [Abstract][Full Text] [Related]
24. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
25. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
28. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of bone marrow lesions in children with neuroblastoma detected by flow cytometry].
Popov AM; Shorikov EV; Verzhditskaia TIu; Tsaur GA; Druĭ AE; Solodovnikov AG; Savel'ev LI; Fechina LG
Vopr Onkol; 2014; 60(4):469-75. PubMed ID: 25552066
[TBL] [Abstract][Full Text] [Related]
30. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
31. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
33. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences.
Kriangkum J; Taylor BJ; Treon SP; Mant MJ; Reiman T; Belch AR; Pilarski LM
Clin Cancer Res; 2007 Apr; 13(7):2005-13. PubMed ID: 17404080
[TBL] [Abstract][Full Text] [Related]
35. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
36. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
[TBL] [Abstract][Full Text] [Related]
38. Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas.
Mazur G; Hałoń A; Wróbel T; Jeleń M; Kuliczkowski K
Neoplasma; 2004; 51(3):159-63. PubMed ID: 15254666
[TBL] [Abstract][Full Text] [Related]
39. Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.
Owen RG; Johnson SA; Morgan GJ
Hematol Oncol; 2000 Jun; 18(2):41-9. PubMed ID: 10960874
[No Abstract] [Full Text] [Related]
40. Immunohistochemical phenotyping of plasma cells in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia is comparable to flow cytometric techniques.
Howard MT; Hodnefield J; Morice WG
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):96-8. PubMed ID: 21454202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
